tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

SAGE Stock Latest News

SAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties
RatingsSAGE Therapeutics: Hold Rating Maintained Amid Steady Growth and Strategic Uncertainties
1M ago
SAGE
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty
PremiumCompany Announcements
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty
1M ago
SAGE
SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments
PremiumRatings
SAGE Therapeutics: Hold Rating Amid Uncertainty in Sales Growth and Strategic Developments
1M ago
SAGE
Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects
PremiumRatings
Cautious Hold Rating on SAGE Therapeutics Amid Uncertain Growth Prospects
1M ago
SAGE
Sage Therapeutics Reports Strong Q1 2025 Performance
PremiumCompany Announcements
Sage Therapeutics Reports Strong Q1 2025 Performance
1M ago
SAGE
Cautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties
PremiumRatingsCautious Hold Rating on SAGE Therapeutics Amid Financial Pressures and Strategic Uncertainties
1M ago
SAGE
Sage Therapeutics reports Q1 EPS ($1.01), consensus ($1.01)
Premium
The Fly
Sage Therapeutics reports Q1 EPS ($1.01), consensus ($1.01)
1M ago
SAGE
Is SAGE a Buy, Before Earnings?
Premium
Pre-Earnings
Is SAGE a Buy, Before Earnings?
1M ago
SAGE
Cautious Outlook on SAGE Therapeutics: Hold Rating Maintained Amid EPS Adjustments and Revenue Forecast Revisions
PremiumRatings
Cautious Outlook on SAGE Therapeutics: Hold Rating Maintained Amid EPS Adjustments and Revenue Forecast Revisions
1M ago
SAGE
Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
PremiumRatings
Cautious Outlook for SAGE Therapeutics Amid Strategic Uncertainty and Financial Challenges
2M ago
SAGE
Sage Therapeutics resumed with an Underperform at BofA
PremiumThe Fly
Sage Therapeutics resumed with an Underperform at BofA
3M ago
BIIB
SAGE
SAGE Therapeutics Announces CMO Resignation and Interim Appointment
PremiumCompany Announcements
SAGE Therapeutics Announces CMO Resignation and Interim Appointment
3M ago
8K
SAGE
Sage Therapeutics Chief Medical Officer to step down
PremiumThe FlySage Therapeutics Chief Medical Officer to step down
3M ago
SAGE
SAGE Therapeutics: Hold Rating Amid Gradual Growth Prospects and Market Challenges
Premium
Ratings
SAGE Therapeutics: Hold Rating Amid Gradual Growth Prospects and Market Challenges
3M ago
SAGE
Sage Therapeutics price target established at JPMorgan
Premium
The Fly
Sage Therapeutics price target established at JPMorgan
3M ago
SAGE
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
PremiumCompany Announcements
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth
4M ago
SAGE
Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects
PremiumRatings
Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects
4M ago
SAGE
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges
PremiumCompany Announcements
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges
4M ago
SAGE
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
PremiumThe Fly
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
4M ago
BIIB
SAGE
Sage Therapeutics price target lowered to $7 from $9 at Baird
PremiumThe FlySage Therapeutics price target lowered to $7 from $9 at Baird
4M ago
SAGE
Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities
Premium
Ratings
Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities
4M ago
SAGE
Sage Therapeutics price target lowered to $8 from $9 at Canaccord
Premium
The Fly
Sage Therapeutics price target lowered to $8 from $9 at Canaccord
4M ago
BIIB
SAGE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >